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BACKGROUND: Overall, the incidence of male reproductive disorders has increased in recent decades. Testicular development during
fetal life is crucial for subsequent male reproductive function. Non-genomic factors such as environmental chemicals, pharmaceuticals and
lifestyle have been proposed to impact on human fetal testicular development resulting in subsequent effects on male reproductive health.
Whilst experimental studies using animal models have provided support for this hypothesis, more recently a number of experimental stud-
ies using human tissues and cells have begun to translate these findings to determine direct human relevance.
OBJECTIVE AND RATIONALE: The objective of this systematic review was to provide a comprehensive description of the evidence
for effects of prenatal exposure(s) on human fetal testis development and function. We present the effects of environmental, pharmaceut-
ical and lifestyle factors in experimental systems involving exposure of human fetal testis tissues and cells. Comparison is made with existing
epidemiological data primarily derived from a recent meta-analysis.
SEARCH METHODS: For identification of experimental studies, PubMed and EMBASE were searched for articles published in English
between 01/01/1966 and 13/07/2018 using search terms including ‘endocrine disruptor’, ‘human’, ‘fetal’, ‘testis’, ‘germ cells’, ‘testoster-
one’ and related search terms. Abstracts were screened for selection of full-text articles for further interrogation. Epidemiological studies
involving exposure to the same agents were extracted from a recent systematic review and meta-analysis. Additional studies were identi-
fied through screening of bibliographies of full-texts of articles identified through the initial searches.
OUTCOMES: A total of 25 experimental studies and 44 epidemiological studies were included. Consistent effects of analgesic and phthal-
ate exposure on human fetal germ cell development are demonstrated in experimental models, correlating with evidence from epidemio-
logical studies and animal models. Furthermore, analgesic-induced reduction in fetal testosterone production, which predisposes to the
development of male reproductive disorders, has been reported in studies involving human tissues, which also supports data from animal
and epidemiological studies. However, whilst reduced testosterone production has been demonstrated in animal studies following expos-
ure(s) to a variety of environmental chemicals including phthalates and bisphenol A, these effects are not reproduced in experimental
approaches using human fetal testis tissues.
WIDER IMPLICATIONS: Direct experimental evidence for effects of prenatal exposure(s) on human fetal testis development and func-
tion exists. However, for many exposures the data is limited. The increasing use of human-relevant models systems in which to determine
the effects of environmental exposure(s) (including mixed exposures) on development and function of human tissues should form an
important part of the process for assessment of such exposures by regulatory bodies to take account of animal–human differences in
susceptibility.
Key words: human fetus / testis / endocrine disruptor / environmental chemical / pharmaceutical / testosterone / germ cell / Leydig
cell / Sertoli cell / steroidogenesis
Introduction
Development of the male reproductive system and its subsequent
function is impacted by events that occur in utero. Perturbations in
testicular development or function during fetal life may result in male
reproductive disorders that present postnatally (van den Driesche
et al., 2017). This includes anatomical abnormalities identified at birth,
such as cryptorchidism and hypospadias, or disorders presenting in
adulthood, including testicular cancer or infertility (Sharpe and
Skakkebaek, 2008). These associated disorders are collectively
referred to as the testicular dysgenesis syndrome (TDS). The devel-
opment of TDS has been shown in rats to be influenced by a reduc-
tion in androgen production or action during a key period of fetal life,
known as the masculinization programming window (MPW) (Welsh
et al., 2008; van den Driesche et al., 2017). The increasing incidence
of TDS disorders over recent decades, highlights the potential
importance of environmental impacts in their etiology (Skakkebaek
et al., 2016). Environmental factors that have been proposed to affect
fetal testis development and predispose to TDS disorders include
environmental chemicals (e.g. plasticizers and pesticides), pharmaceu-
ticals (e.g. analgesics, metformin and diethylstilboestrol) and lifestyle
factors (e.g. diet, alcohol and smoking) (Habert et al., 2014; Kilcoyne
and Mitchell, 2017).
In order to understand how in-utero exposures might disrupt fetal
development and result in postnatal testicular disorders, it is import-
ant to consider the normal development of the germ and somatic cell
populations in the human fetal testis (Fig. 1). During fetal life, germ
cells migrate into the developing gonad (4–5 weeks in human) where
they undergo differentiation from gonocytes to spermatogonia. This
transition takes place during fetal and early postnatal life and involves
the loss of expression of pluripotency factors (e.g. POU5F1) and gain
of differentiated germ cell-specific protein expression (e.g. MAGEA4)
(Mitchell et al., 2008). Failure of gonocyte differentiation can result in
the development of pre-malignant germ cell neoplasia in-situ cells
(GCNIS), which results in the development of testicular germ cell
cancer (TGCC) in adulthood (Rajpert-De Meyts et al., 2016) whilst
loss of germ cells as a result of in-utero events can also potentially
impact future fertility.
Germ cell development during fetal life is supported by somatic cells
that form the germ-stem cell niche. Sertoli cells surround the gonocytes,
forming seminiferous cords, at ~6–7 gestational weeks (GW) in the
human (O’Shaughnessy and Fowler, 2011; Heeren et al., 2015). Sertoli
cells are fundamental for germ cell development (Bitgood et al., 1996),
regression of the Müllerian ducts (AMH, anti-Müllerian hormone) and
initiation of fetal Leydig cell differentiation (Pierucci-Alves et al., 2001;
Yao et al., 2002; Griswold and Behringer, 2009).
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Fetal Leydig cells are present in the interstitium of the testis from six
GWs in humans and are responsible for the production of hormones
involved in testicular descent. Insl3 is involved in the transabdominal
phase of testicular descent, whilst testosterone is required to enable the
testis to traverse the inguinal canal (Hughes and Acerini, 2008). Leydig
cell-derived testosterone is also converted to dihydrotestosterone
(DHT) in peripheral tissues for masculinization of the fetus, which
includes development of external genitalia. Therefore, perturbations to
the function of fetal Leydig cells can predispose to the development of
male reproductive disorders including TDS and some disorders of sex
development (DSD) (van den Driesche et al., 2017).
The majority of experimental studies investigating the effects of
environmental exposures on fetal testis development and function
involve rodents. These studies have provided a large amount of valu-
able information highlighting the potential for effects of in-utero
exposure to a wide variety of environmental chemicals on male
reproductive development. However, there are important differences
in fetal testicular development between rodent and human in terms
of germ cell development (McKinnell et al., 2013) and steroidogenesis
(Scott et al., 2009). Furthermore, the exposures used for these stud-
ies may not reflect the levels of exposure that are directly relevant to
humans. Assessment of experimental studies using experimental ani-
mal models must take account of the variations in model systems (in-
vitro versus in-vivo), exposure regimen and drug metabolism, whilst
also accounting for the impact of species differences for each of these
parameters (Kilcoyne and Mitchell, 2017). As a result, animal studies
often report findings based on relative exposures which exceed
human-relevant exposures, often by several orders of magnitude.
In order to gain information on the potential for in-utero environ-
mental exposures to impact development of male reproductive disor-
ders in humans, epidemiological studies can be employed. A recent
systematic review has described the epidemiological evidence for
associations between prenatal exposures and male reproductive dis-
orders in humans (Bonde et al., 2016). A number of important con-
siderations must be applied when assessing epidemiological evidence
for such associations. These include, but are not limited to (i) the
relevance and/or size of the population group, (ii) measurement of
the exposure (direct/indirect) (iii) biological plausibility for the expos-
ure alone causing the effect and elimination of potential confounders
(reviewed in Foster et al., 2017) (Fig. 2 and Table I).
While human epidemiological and animal experimental studies are
extremely informative, there remains a large gap in our understanding
of how specific environmental exposures may directly affect the
human fetal testis. Therefore, development of model systems using
human fetal tissues and human-relevant doses can bridge the gap
between direct evidence from animal experimental models and indir-
ect evidence based on epidemiological data. A number of recent
studies have utilized in-vitro or xenograft approaches using human
fetal testis tissues to determine the effect of environmental and
pharmaceutical exposures. As with epidemiological studies, there are
a number of key considerations when interpreting the results of these
studies relating to model system, exposure regimen and biological
relevance of the measured outcome (Fig. 2 and Table I).
A comprehensive review of the experimental evidence for effects
of environmental exposures on fetal testicular development and func-
tion using human cells or tissues has not previously been reported.
This systematic review will detail the experimental evidence for
impacts of environmental chemicals, pharmaceuticals and lifestyle fac-
tors on human fetal testis development and function. For each class
of exposure for which human experimental evidence exists, we will
first summarize the findings of animal studies and then provide a crit-
ical review of the epidemiological evidence. We will then describe in
detail the evidence to support or refute these findings based on
experimental models using human fetal testis tissues.
Figure 1 Testicular development and function during fetal life and reproductive disorders associated with testicular dysgenesis
syndrome. DHT, dihydrotestosterone.
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Methods
The study was designed as a systematic review of the published literature
relating to the effects of in-utero exposures on human fetal testis develop-
ment and function in experimental models. The study followed the princi-
ples of the PRISMA guidelines for reporting systematic reviews (Moher
et al., 2009). The protocol for searching and assessing the literature was
determined prior to the start of the literature search. It is not currently
possible to register laboratory experimental studies with PROSPERO.
Information sources
We performed an online search of PubMed and EMBASE (13/07/2018)
to identify all experimental studies relating to testicular effects of fetal
exposures to environmental, pharmaceutical and lifestyle factors, limited
to studies utilizing human fetal tissues or cells. For identification of rele-
vant epidemiological studies, we included the publications identified in a
recent systematic review and meta-analysis of associations between pre-
natal exposures and male reproductive disorders (Bonde et al., 2016).
Additional epidemiological studies were identified from the reference lists
of the screened articles.
Eligibility for inclusion
We performed a systematic search of original publications according to
the following criteria for inclusion: English language articles published
between 01/01/1966 and 13/07/2018; experimental studies on expos-
ure of human fetal testis tissue or cells to a clearly defined environmental,
pharmaceutical or lifestyle factor; and outcomes including effects on
testicular hormone production (e.g. testosterone, Insl3, AMH), germ or
somatic (Sertoli, Leydig) cell development.
Exclusion criteria
We excluded studies according to the following criteria: exposure of tis-
sues or cells representative of a period other than fetal life; exposure of
non-testicular tissues or cells; outcomes other than those described
above; and review articles.
Search and study selection
We searched the databases using a combination of medical subject head-
ings and generic terms relating to effects of exposures on human fetal tes-
tis development (Supplementary Table S1). We identified 3229 hits. Both
authors screened the titles and/or abstracts independently to assess eligi-
bility. Full texts were requested for studies that included in the abstract
the use of human fetal testis tissue or cells and the effect of exposure to
environmental, pharmaceutical or lifestyle factors. Full texts for 40 studies
were obtained and a total of 25 publications were included in the review
of experimental evidence (Supplementary Table S2; Fig. 3). A total of 15
studies were excluded (Supplementary Table S3). A further 44 publica-
tions were included in the review of epidemiological evidence
(Supplementary Table S4).
Summary measures
Studies included in-vitro and ex-vivo (xenograft) approaches and results
were assessed primarily for effects on testosterone secretion and on
germ cell number (both expressed as % change compared to vehicle
Figure 2 Comparison of approaches to comparing the effects of environmental and pharmaceutical exposures on human fetal
testis development and function. TGCC, testicular germ cell cancer.
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control). Effects on additional testicular hormones, AMH (produced by
SC) and Insl3 (produced by LC) are also reported.
Results
The distribution of studies based on exposure type and year of publi-
cation is shown in Fig. 4. The majority of the studies were published
from 2007 to 2018. The earlier studies primarily investigated phtha-
lates, pesticides and smoking, whilst more recent studies have mainly
focused on bisphenols and analgesics.
Environmental chemicals
Phthalates
Phthalates are a class of industrial chemicals used mainly to soften
polyvinyl chloride-based products and are found in a wide array of
general plastic products. Exposure to phthalates may occur via inhal-
ation, ingestion or direct contact with items including packaging, oils,
food storage and personal care products. Phthalates are not stored
in the body but are instead rapidly metabolized into monoesters with
a urinary excretion half-life of <24 h (Koch et al., 2012). Commonly
used plasticisers over recent decades include di-(2-ethylhexyl) phthal-
ate (DEHP) which is converted to its monoester metabolite, mono-
2-ethylhexyl phthalate (MEHP) and di-n-butyl phthalate (DBP), which
is metabolized to mono-n-butyl phthalate MBP. In 2015, DEHP was
banned from general use under EU law under the REACH restriction
(Registration, Evaluation, Authorization and Restriction of Chemical
Substances) and has been replaced by di-isononyl phthalate (DiNP),
and more recently di-isononyl cyclohexane-1,2-dicarboxylate
(DINCH), both of which are deemed less biologically active (Gray
et al., 2000). Recent biomonitoring data has shown that DiNP meta-
bolites measured in human urinary samples are increasing in both
America (Silva et al., 2013) and Europe (Goen et al., 2011).
Table I Key considerations for the assessment of human studies using epidemiological, or experimental (xenograft or
in-vitro) approaches.
Epidemiology Xenograft In vitro
Population Potential limitation—population/tissue used may be unrepresentative of target population/tissue
• Is the population studied representative of the
target population (e.g. pregnant women)?
• Is the tissue representative of the
target population (e.g. fetal
tissue)?
• Is the tissue representative of the target
population (e.g. fetal tissue or cells)?
Agent Potential limitation—agent under investigation may be not be representative of the exposure under investigation (e.g. metabolite) or there
may be additional confounding agents
• Is the relevant agent being measured in the
population?
• Is there potential for confounding by other/
similar exposures?
• Is the investigated agent relevant
to potential human exposure?
• Is it metabolized in the host
animal to an active/inactive form
(e.g. DBP–MBP)?
• Is the investigated agent relevant to potential
human exposure?
• Is the active agent or metabolite added to the
medium?
Exposure Potential limitation—assessment of exposure in epidemiological studies or regimen used in experimental studies may not accurately reflect
true human exposure
• Is the exposure measured in the subjects (e.g.
indirect measurement of fetal exposure through
maternal serum/urine) or indirectly assessed
(e.g. self-report) and does this accurately
capture actual fetal exposure?
• Is the dose, frequency, duration
and route of exposure?
representative of human exposure
(e.g. pharmaceuticals)?
• Is the concentration of agent placed in the
media representative of human levels (e.g.
maternal serum, amniotic fluid, fetal serum)
and/or human dosing regimen?
Timing Potential limitation—timing of assessment of exposure in epidemiological studies or developmental stage of tissue used in experimental
studies may not accurately reflect the relevant stage
• Is exposure measured at the appropriate
developmental stage (e.g. trimester of fetal life
or MPW)?
• Does timing and frequency of measurement
accurately reflect internal exposure?
• Is the transplanted tissue at the
same developmental stage (e.g.
trimester of fetal life or MPW)?
• Does the experimental system
maintain tissue development and
function?
• Is the tissue cultured at the same
developmental stage (e.g. trimester of fetal life
or MPW)?
• Does the experimental system maintain tissue
development and function?
Effect Potential limitation—the effects of exposure may be measured directly or through association and direct effects of exposure may not result
in clinical consequences
• Is there a direct clinical association with fetal
exposure (e.g. cryptorchidism) or is it a
surrogate marker for clinical effects (e.g. AGD)?
• What is the magnitude of effect and is it
statistically significant?
• Is there a plausible mechanism?
• Is the effect clinically relevant (e.g.
potential for reduced
testosterone to induce
cryptorchidism)?
• What is the magnitude of effect
and is it statistically significant?
• Has the mechanism for the effect
been defined?
• Is the effect relevant to in-vivo situation?
• Is the effect clinically relevant (e.g. potential
for reduced testosterone to induce
cryptorchidism)?
• What is the magnitude of effect and is it
statistically significant?
• Has the mechanism for the effect been
defined?
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Animal studies
The majority of published experimental studies investigating the
effects of in-utero exposure to certain phthalates (primarily DEHP or
DBP) have used rodent models and have demonstrated a disruption
of normal fetal testis development and subsequent development of
male reproductive disorders, resulting from decreased fetal testosterone
production in male offspring (Parks et al., 2000; Mylchreest et al., 2002;
Habert et al., 2014; Kilcoyne et al., 2014; Fisher et al., 2016).
Moreover, effects primarily result from exposure during the MPW
(Welsh et al., 2008; Kilcoyne et al., 2014; van den Driesche et al.,
2017) which is believed to equate to ~8–14 weeks gestation in
humans (Scott et al., 2009; Fowler et al., 2011).
Epidemiology - DBP/MBP
In humans, DBP is rapidly metabolized (primarily to MBP) and
excreted (Koch et al., 2012). Therefore measuring the effects of
phthalate exposure on fetuses in pregnant women is challenging.
Despite this, urinary concentrations of several phthalate metabolites
(including MBP) have been shown to be positively correlated with the
incidence of male developmental abnormalities in the newborn, such
as cryptorchidism and shortened anogenital distance (AGD; a bio-
logical readout of fetal testosterone exposure) (Marsee et al., 2006).
Further indirect evidence for effects of maternal MBP/DBP exposure
on steroidogenesis in the human fetal testis has also been reported in
retrospective association studies (Marsee et al., 2006; Swan, 2008).
These studies demonstrate a negative correlation between maternal
urinary MBP concentration and AGD in males, although the changes
are minor. However, a separate small prospective study failed to find
any correlation (Huang et al., 2009). Furthermore, whilst an associ-
ation between urinary MBP during second and third trimester and
AGD has been demonstrated (Swan et al., 2005), a similar study has
shown no such association when urinary MBP is measured during the
first trimester (Swan et al., 2015).
Several phthalate monoesters have been detected in maternal
breast milk over a large concentration range (1.5–1 410 μg/L) and
these have been correlated with infant hormone levels (Main et al.,
2006). Despite the reported association between phthalates (includ-
ing MBP) in maternal breast milk and altered testosterone levels of
infant males (Main et al., 2006), a recent study did not detect signifi-
cant associations between MBP concentrations in breast milk and
either testosterone or INSL3 in newborns (Chevalier et al., 2015).
Importantly, this study found no association between MBP in breast
milk and the presence of cryptorchidism, consistent with maternal
MBP concentrations postnatally not being associated with human fetal
testosterone production.
Phthalates, including DBP, have also been used in the enteric coat-
ing of several commonly used medications including proton pump
inhibitors (e.g. omeprazole) and anti-epileptics (e.g. valproate, carbe-
mazepine) (Kelley et al., 2012; Jamieson and McCully, 2015). This can
result in an increase in urinary phthalate levels in the region of
50–100 times, compared with the general population (Hernandez-
Diaz et al., 2009; Seckin et al., 2009; Hait et al., 2014). As a result, it
Figure 3 Prisma flow diagram for identification and selection of studies. #Supplementary Table S2; *Supplementary Table S3.
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may be expected that the regular use of these medications during
pregnancy may be associated with an increased risk of male repro-
ductive disorders in the offspring of exposed mothers. DBP has been
used in the coating of mesalazine (a 5-aminosalicylic acid drug), an
anti-inflammatory agent used to treat inflammatory bowel disease
(IBD). Several studies have reported the pregnancy outcomes for
women taking 5-ASA drugs during pregnancy and a meta-analysis of
2200 pregnant women with IBD has reported no increased incidence
of congenital abnormalities as a result of exposure to mesalazine dur-
ing pregnancy (n = 642), in comparison to non-exposed mothers
with IBD (n = 1158) (Rahimi et al., 2008). It is important to point out
that a limitation of the studies included in the meta-analysis is that
they were not specifically designed to identify associations with male
reproductive disorders; however, it is reassuring to note that none of
the studies to date have reported an increase in the development of
these disorders. Prospective studies designed to answer this specific
question would be desirable, although conducting such studies will be
challenging due to the widespread removal of DBP from these
medications.
Epidemiology - DEHP/MEHP
DEHP has been detected in fetal cord blood samples (of 1.1 ×
10−8 M) and cord blood of newborns (Latini et al., 2003; Lin et al.,
2011), demonstrating that fetal exposure to DEHP can begin from an
early stage. MEHP, measured in the urine of pregnant women (n = 111;
9–40 weeks gestation) has been associated with a significant reduction
in AGD in male offspring (Suzuki et al., 2012). DEHP metabolites in
pregnant women during the first trimester have been shown to be sig-
nificantly and inversely related with AGD in male newborns (n = 366)
(Swan et al., 2015), whereas no such association was identified for
maternal urinary MEHP in second or third trimesters (Swan et al.,
2005). A similar inverse relationship between the anoscrotal distance
(AGDas) in newborn males (n = 168) and maternal DEHP metabolite,
concentrations specifically during the first trimester, has also been
described (Martino-Andrade et al., 2016). These findings are in contrast
to a Swedish study which found no significant association between first
trimester concentrations of DEHP metabolites in mothers and AGDas
in 196 males aged 21 months (Bornehag et al., 2015). Interestingly, this
is despite the authors reporting a significant association between
AGDas (4% reduction) and some DiNP metabolites (Bornehag et al.,
2015).
The timing of measurement of exposure may be important given
that whilst an association between first trimester maternal urine con-
centrations of DEHP and AGDas have been described, no association
was found for second or third trimester DEHP concentrations
(Martino-Andrade et al., 2016). Another recent study measured
Figure 4 Number of publications involving experimental exposures to environmental agents and pharmaceuticals using human
fetal testis tissues or cells. DES, diethylstilboestrol. For (A) ‘All Publications’, a breakdown of the investigated agents into (B) environmental,
(C) pharmaceutical and (D) lifestyle is included. NB: Some publications include exposure to several different agents.
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urinary phthalates (including DEHP metabolites) concentration in
pregnant women during late second and third trimester and reported
no association between prenatal phthalate exposure and AGD in
male offspring (n = 273) at 3 months of age (Jensen et al., 2016).
Furthermore, a study involving measurement of 5cx-MEPP (a DEHP
metabolite) in amniotic fluid during the second trimester found no
association with cryptorchidism or hypospadias (Jensen et al., 2015).
Experimental evidence from human studies
Investigating phthalate exposure directly using human fetal testis is
challenging; however, several studies have utilized in-vitro cell or tissue
culture and/or in-vivo xenograft models to explore potential human
effects (Table II).
DBP/MBP - Hormones. Effects of exposure to DBP/MBP have been
investigated in human fetal testis tissues using in-vitro or xenograft
approaches. In-vitro exposure of second trimester human fetal testis
explants to MBP had no effect on (basal or hCG stimulated) testos-
terone production after 48 h (Hallmark et al., 2007), whilst the same
study demonstrated a reduction in testosterone production in fetal
rat testis explants after hCG stimulation (Hallmark et al., 2007). Use
of an ex-vivo xenograft system may represent a more physiological
approach to investigating potential effects of phthalates on the human
fetal testis. Despite several studies xenografting first and/or second
trimester human fetal testes into different host species, and at differ-
ent locations (rat; renal subcapsular space) (Heger et al., 2012; Spade
et al., 2014) (mouse; subcutaneous tissue) (Mitchell et al., 2012), no
effects on steroidogenic gene expression, seminal vesicle weight or cir-
culating testosterone levels were identified at levels of exposure equiva-
lent to those used in rat pregnancy studies, which are far in excess of
human exposure. This included varying duration of DBP exposure for 4
or 21 days (Mitchell et al., 2012) or for 14 days (Heger et al., 2012;
Spade et al., 2014). Furthermore, substituting MBP instead of DBP for
21 days also had no effect on testosterone production from xenografts
(Mitchell et al., 2012). Exposure of human fetal testis xenografts to DBP
at varying doses (100, 250, 500mg/kg) over a more limited time-
window (24, 48, 72 h) did not alter mRNA expression of Leydig cell
genes including several steroidogenic genes and the hormone Insl3 (pro-
duced by Leydig cells and involved in testicular descent) (Heger et al.,
2012).
Further support for the lack of effect of exposure to DBP/MBP on
testosterone production and development of male reproductive dis-
orders in primates is evident following in-utero exposure of marmoset
monkeys to MBP (McKinnell et al., 2009). Pregnant marmosets (n =
5–6) were dosed with 500 mg/kg MBP from ~7 to 15 weeks gesta-
tion and testicular and male reproductive effects were assessed in the
neonate or adult. No effects on testicular morphology or germ cell
number were identified at birth or adulthood following in-utero MBP
exposure and testosterone levels at birth were unaffected.
Importantly, there were no cases of hypospadias, cryptorchidism,
impaired spermatogenesis or focal testicular dysgenesis in any of the
exposed animals (McKinnell et al., 2009).
DBP/MBP - Germ cells. Despite the lack of effect of DBP exposure on
testosterone production or steroidogenic gene expression in the
human fetal testis, abnormal morphology of germ cells within the
seminiferous cords has been described following DBP exposure in
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the xenograft model, including an increase in the number of multi-
nucleated gonocytes (MNGs) (Heger et al., 2012). Furthermore,
DBP-exposure (500 mg/kg) for 21 days in a similar xenograft model
reduced the number of gonocytes and induced a higher proportion
of MNGs in human fetal testes (van den Driesche et al., 2015b).
These effects of DBP exposure, namely reduced gonocyte number
and increased MNGs, is in keeping with findings from rodent studies
using comparable DBP exposure (Ferrara et al., 2006; Jobling et al.,
2011; van den Driesche et al., 2015b).
DEHP/MEHP - Hormones. In-vitro exposure of human first trimester
testis to a range of doses of MEHP (10−4, 10−5, 10−6 M) using an
organotypic culture system resulted in unchanged testosterone (basal
or LH-stimulated) production compared to control after 72 h of cul-
ture (Lambrot et al., 2009). In keeping with a lack of effect on Leydig
cell function, there was also no change in gene expression of steroi-
dogenic enzymes or Insl3 (Lambrot et al., 2009). These results are in
keeping with similar in-vitro (Hallmark et al., 2007) and xenograft
(Heger et al., 2012; Mitchell et al., 2012; Spade et al., 2014) studies
involving DBP/MBP exposure of human fetal testis tissue.
In addition to assessing effects of MEHP exposure on testosterone
production in the human fetal testis, exposure of first trimester testis
(7–12 weeks gestation) to 10−4 M MEHP for 72 h resulted in a reduc-
tion in AMH mRNA, although Sertoli cell-derived AMH protein
expression was not affected (Lambrot et al., 2009).
DEHP/MEHP - Germ cells. Exposure of human first trimester testis
tissue to MEHP (10−5 M) in-vitro via an organotypic culture system
resulted in an approximately 40-50% increase in apoptotic gonocytes
compared to control testis tissue (Muczynski and Cravedi et al.,
2012). In-vitro studies using mouse fetal testis tissue conducted in par-
allel, demonstrated similar effects with a 30% reduction in gonocyte
number and a 4-fold increase in the rate of apoptotic gonocytes
(Muczynski and Lecureuil et al., 2012). These results support the find-
ings of a previous study in first trimester human fetal testes exposed
to a range of doses of MEHP (10−4, 10−5, 10−6 M) for 72 h. Using a
similar in-vitro system, MEHP-exposure resulted in a 40% reduction in
germ cell number via increased apoptosis (without altering GC prolif-
eration) at both 10−4 and 10−5 M MEHP under basal conditions,
whilst 10−5 M MEHP resulted in a reduction in gonocyte number
under basal and LH-stimulated conditions (Lambrot et al., 2009). As
described for DBP/MBP, the germ cell effects were similar between
MEHP-exposed human and mouse fetal testes, as gonocyte number
was also significantly reduced in mouse fetal testes after MEHP
exposure, via an increase in apoptotic gonocytes (Chauvigne et al.,
2009; Lehraiki et al., 2009). However, in-vitro organ culture of fetal
rat testes (at embryonic Day 13 or 18) with MEHP showed no effect
on the mitotically quiescent germ cells (Li and Kim, 2003).
Summary—phthalates
Exposure to DBP/DEHP has consistently been shown to reduce fetal
testosterone production resulting in a high frequency of TDS disor-
ders in rats, whereas epidemiological studies have reported inconsist-
ent associations between maternal phthalate exposures and indirect
measures of fetal testosterone production, namely AGD, and no
studies have reported an association between phthalate exposure
and either cryoptorchidism or hypospadias. In addition, no effects of
phthalates on testosterone production have been described in
experimental models using in-vitro culture or xenografting of human
fetal testis tissues and a single in-vivo study in a non-human primate.
This is despite administration of phthalate doses that far exceed
environmental/human exposure levels and includes exposure during
the proposed MPW. Furthermore, the in-vivo study involving in-utero
exposure of marmoset monkeys failed to demonstrate the develop-
ment of male TDS disorders that result from a reduction in testoster-
one. Taken together the results indicate that exposure to
environmental levels of DBP/DEHP are unlikely to result in effects on
fetal testosterone production in humans. Interestingly, whilst no
effects of phthalate exposure have been demonstrated in human fetal
testes, anti-androgenic effects have been shown to occur in adult
human testis following in-vitro culture, suggesting that the effect of
exposure is dependent on the developmental stage of the testis
(Albert and Jegou, 2014).
However, for germ cells effects, the results of experimental studies
in rodents and human fetal tissues are more consistent, with a reduc-
tion in gonocyte number and an increase in multi-nucleated gono-
cytes being reported in several studies following phthalate exposure.
The implications of these findings in terms of future fertility are
uncertain.
Bisphenols
Bisphenols are synthetic chemicals, widely used in the manufacture of
hard plastic products. Bisphenol A (BPA) is also a component of
epoxy-resins, used as the inner coating of metallic food and beverage
cans. BPA has weak estrogenic properties, albeit several orders of
magnitude less potent than endogenous 17β-oestradiol (Leffers et al.,
2001).
Animal studies
In-vivo rodent studies have reported conflicting results regarding the
effect of in-utero BPA exposure on testosterone production by the
fetal testis. Exposure of pregnant rats to high concentrations of BPA
throughout pregnancy was associated with a reduction in testoster-
one production in male fetuses around birth (Tanaka et al., 2006),
whilst other studies have reported no effect of in-utero exposure to
BPA on AGD in male offspring (Kobayashi et al., 2002; Howdeshell
et al., 2008). In-vitro studies have demonstrated a reduction in testos-
terone production in mouse and rat fetal testis following exposure to
high concentrations of BPA (N’Tumba-Byn et al., 2012). Given the
conflicting results of animal studies involving BPA, a large collabora-
tive study (CLARITY-BPA) is currently being undertaken in rodents
to determine the effects of BPA on a range of body systems including
reproductive organs (Schug et al., 2013). A recent publication from
the consortium reported no effects of combined in-utero and post-
natal exposure on several testicular morphometric and histological
endpoints, including adult testis weight, except at very high doses
that far exceed environmental exposure (Dere et al., 2018).
Epidemiology
A limited number of epidemiological studies have investigated the
relationship between human pregnancy exposure to BPA and male
reproductive disorders. In a study involving measurement of cord
blood in 52 newborn boys with cryptorchidism and 126 controls, no
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association was found between BPA exposure and testosterone;
however, a significant negative correlation between BPA and Insl3
was identified (Chevalier et al., 2015). Given that Insl3 and testoster-
one are both involved in testicular descent, it is interesting to note
that there was no association between BPA levels in cord blood and
cryptorchidism (Fenichel et al., 2012; Chevalier et al., 2015). Similarly,
in another case-control study, no association was identified between
BPA exposure, as measured in maternal urine, and cryptorchidism in
the male offspring (Chevrier et al., 2012). The relationship between
BPA and cryptorchidism has also been investigated in 98 boys with
unilateral cryptorchidism aged 1–4 years. Serum BPA was measured
prior to surgery and a significant association was found between total
BPA and cryptorchidism in boys compared to 57 healthy controls
(Komarowska et al., 2015). However, no association was found
between free (unconjugated) BPA and cryptorchidism and it is of
interest to note the wide variation and high degree of overlap
between the BPA levels of the two groups. An association between
urogenital abnormality (cryptorchidism or hypospadias) and free BPA
levels in term placenta was also described in a study involving 79
boys (Fernandez et al., 2016). In this study, placental BPA was signifi-
cantly higher in the cases compared to controls; however, an associ-
ation between BPA and cryptorchidism/hypospadias was only
apparent for the upper tertile of BPA exposure which included just
26 (12 cases and 14 controls) boys (Fernandez et al., 2016). In add-
ition, this study was not able to assess BPA exposure during fetal life
which temporally separates the measurement of the exposure from
the development of the disorder. An association has been described
between maternal occupational exposure to BPA and AGD in 56
exposed male offspring when compared to 97 unexposed controls
(Miao et al., 2011). Care must be taken when interpreting this data
as the exposure to BPA was determined by personal air sampling
with extrapolation to estimate past exposure for the index
pregnancy.
Experimental evidence from human studies
Several experimental studies have investigated the effect of BPA
exposure using human fetal testis tissue and cells (Table III). A key
consideration when assessing the results of experimental studies
involving effects of exposure(s) on the human fetal testis is the con-
centration/doses to which the tissue is exposed. For BPA, human
internal exposure to unconjugated BPA has been reported to be in
the range 10−2 M to 10−3 M, including in pregnant women
(Vandenberg et al., 2010) and mean cord blood levels have been
reported closer to 10−3 M (Fenichel et al., 2012). However, a recent
study involving 48 samples from 30 healthy pregnant women, which
accounted for potential post-sampling contamination, reported serum
BPA concentrations below the LOD apart from 12 (25%) samples
which ranged from 10−9 to 10−12 M, demonstrating that exposures
may be substantially lower than previously reported (Teeguarden
et al., 2016).
Hormones. A number of studies have investigated the effect of expos-
ure to BPA on testosterone production by human fetal testis tissue
using an in-vitro system (N’Tumba-Byn et al., 2012; Ben Maamar
et al., 2015; Eladak et al., 2015). Exposure of human fetal testis
explants (6–11 GW) to BPA did not affect testosterone production
at a concentration of 10−12 M; however, exposure to higher
concentrations (10−8 to 10−5 M) resulted in a reduction of 20–50%
(N’Tumba-Byn et al., 2012). Further studies have compared the
effect of BPA exposure under basal and gonadotrophin supplemented
conditions (Ben Maamar et al., 2015; Eladak et al., 2015). Exposure
of human fetal testis explants (7–12 GW) to 10−5 M BPA for 72 h
resulted in a significant reduction in testosterone production under
basal (70%), hLH- (30%) and hCG-stimulated (60%) conditions (Ben
Maamar et al., 2015; Gaudriault et al., 2017). However, exposure to
lower concentrations did not result in significant differences except
for 10−8 M under basal conditions in which a 30% reduction was
reported (Ben Maamar et al., 2015). Similar results were obtained in
another study in which exposure to BPA for 72 h under basal condi-
tions resulted in a significant reduction in testosterone production by
human fetal testis tissue (6–11 GW) across a range of concentrations
(10−8 to 10−5 M), whereas reduction in testosterone only occurred
at the highest concentration (10−5 M) under hLH supplemented con-
ditions (Eladak et al., 2015). Two separate studies using the xenograft
system have also investigated the effect of BPA on testosterone pro-
duction using first and second trimester human fetal testis tissue
(Eladak et al., 2015; Eladak et al., 2018). Exposure of host mice to
10−5 M BPA in drinking water for 5 weeks did not affect testosterone
production from xenografted tissue, as measured by host mouse
seminal vesicle weight or serum testosterone. Importantly, the
authors were able to demonstrate that the plasma levels of unconju-
gated and total BPA were significantly higher in the BPA exposed
host mice compared to the vehicle controls. Similarly, for second tri-
mester xenografts, daily oral gavage of host mice with 0.5 or 50 μg/
kg BPA for 5 weeks did not impact on testosterone production
(Eladak et al., 2018). In both xenograft studies, hCG was adminis-
tered to the host mice to mimic the hormonal environment of preg-
nancy as previously described (Mitchell et al., 2010).
The use of gonadotrophin supplementation in the in-vitro and ex-
vivo systems is a key consideration. Supplementation of media with
hCG was able to maintain testosterone levels across the culture peri-
od, as opposed to hLH or basal conditions in which testosterone
levels declined during culture under control (no BPA) conditions (Ben
Maamar et al., 2015). The demonstration that BPA effects are largely
eliminated in the human fetal testis by addition of hLH in the media,
indicates that under physiological conditions of pregnancy, in which
gonadotrophin (hCG and/or LH) levels are extremely high, environ-
mental exposure to BPA is unlikely to affect testosterone production
in the human fetal testis (Eladak et al., 2015). Moreover, a recent
study has investigated the effects of alternative bisphenols that have
been proposed as replacements for BPA (Eladak et al., 2015). For
unstimulated conditions, similar effects to those of BPA occurred fol-
lowing exposure to high concentrations of BPS, BPE and BPF,
although the effects tended to be of lower magnitude and towards
the higher concentrations compared to BPA (Eladak et al., 2015;
Gaudriault et al., 2017).
AMH production from Sertoli cells appears to be unchanged as a
result of BPA exposure in the human fetal testis (Ben Maamar et al.,
2015).
Insl3 is reduced following in-vitro exposure of human fetal testis to
BPA (Ben Maamar et al., 2015). This occurred only at the highest
(10−5 M) and lowest (10−8M) concentrations of BPA tested and also
only under basal conditions. However, levels of Insl3 were generally
much lower in these basal conditions than in media supplemented with
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Table III Summary of experimental studies investigating effects of bisphenol exposure in human fetal testis tissue.
Model and regimen Results
Exposure Model Fetal age
(weeks)
Dose Route Regimen Supplemented Testosterone AMH Insl3 Germ
cells
Study Comments
BPA In-vitro 6–11 10−5 M Media 24–72 h LH ↓ (40–50%) Eladak et al. (2015)
In-vitro 6–11 10−8 to 10−5 M Media 24–72 h Nil ↓ (20–50%)* Eladak et al. (2015) *(10−8 not significant at 24 h)
In-vitro 6–11 10−8 to 10−5 M Media 24–72 h LH ↔ Eladak et al. (2015)
In-vitro 6–11 10−8 to 10−5 M Media 24–72 h Nil ↓ (20–50%) N-Tumba Byn (2012)
In-vitro 6–11 10−12 M Media 24–72 h Nil ↔ N-Tumba Byn (2012)
In-vitro 6–12 10−5 M Media 72 h LH ↓ Eladak et al. (2018) 70% ↑ apoptotic gonocytes
In-vitro 6–12 10−8 to 10−6 M Media 72 h LH ↔ Eladak et al. (2018)
In-vitro 7–12 10−5 M Media 72 h Nil ↓ (70%) ↔ ↓ Ben Mamaar (2015)
In-vitro 7–12 10−5 M Media 72 h hCG ↓ (60%) ↔ ↔ Ben Mamaar (2015)
In-vitro 7–12 10−5 M Media 72 h LH ↓ (30%) ↔ ↔ Ben Mamaar (2015)
In-vitro 7–12 10−8 to 10−6 M Media 72h LH ↔ ↔ ↔ Ben Mamaar (2015)
In-vitro 7–12 10−8 to 10−6 M Media 72 h hCG ↔ ↔ ↔ Ben Mamaar (2015)
In-vitro 7–12 10−8 to 10−6 M Media 72 h Nil ↔** ↔ ↔*** Ben Mamaar (2015) **30% ↓ (10−8), ***70% ↓ (10−8)
and 60% ↓ (10−5)
In-vitro 10–12 10−5 M Media 72 h hCG ↓ (60%) Gaudriault et al. (2017)
In-vitro 10–12 10−6 M Media 72 h hCG ↔ Gaudriault et al. (2017)
Xenograft 9–11 10−5 M Drinking Water 5 weeks hCG ↔ ↓ (19%)# Eladak et al. (2018) #19% ↓ gonocytes
(↑spermatogonia)
Xenograft 14–18 0.5, 50 ug/kg Oral Gavage 5 weeks hCG ↔ Eladak et al. (2018)
BPB In-vitro 10–12 10−5 to 10−4 M Media 72 h hCG ↓ (25–90%) Gaudriault et al. (2017)
In-vitro 10–12 10−8 to 10−6 M Media 72 h hCG ↔ Gaudriault et al. (2017)
BPE In-vitro 10–12 10−4 M Media 72 h hCG ↓ (80%) Gaudriault et al. (2017)
In-vitro 10–12 10−7 to 10−5 M Media 72 h hCG ↔ Gaudriault et al. (2017)
BPF In-vitro 6–11 10−8 M Media 72 h Nil ↔ Eladak et al. (2015)
In-vitro 6–11 10−6 to 10−5 M Media 72 h Nil ↓ (30–40%) Eladak et al. (2015)
In-vitro 10–12 10−4 M Media 72 h hCG ↓ (60%) Gaudriault et al. (2017)
In-vitro 10–12 10−8 to 10−5 M Media 72 h hCG ↔ Gaudriault et al. (2017)
BPS In-vitro 6–11 10−8 to 10−7 M Media 72 h Nil ↔ Eladak et al. (2015)
In-vitro 6–11 10−6 to 10−5 M Media 72 h Nil ↓ (50%) Eladak et al. (2015)
In-vitro 10–12 10−5 to 10−4 M Media 72 h hCG ↓(20–85%) Gaudriault et al. (2017)
In-vitro 10–12 10−8 to 10−6 M Media 72 h hCG ↔ Gaudriault et al. (2017)
Significant effects associated with adverse outcomes are highlighted in red, no change or significant effects not expected to result in adverse outcomes are highlighted in green.
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hLH or hCG. For gonadotrophin supplemented cultures, BPA did not
affect Insl3 production at any of the concentrations tested, similar to the
results already described for testosterone (Ben Maamar et al., 2015).
Germ cells. A recent study has investigated the effects of BPA expos-
ure on germ cells in the human fetal testis. For first trimester testis
(6–12 GW) using the in-vitro approach, exposure to 10−5 M BPA
resulted in a significant increase in the number of apoptotic gonocytes
after 72 h, although there was no effect on apoptosis at lower con-
centrations (Eladak et al., 2018). In xenografts, long-term (5 weeks)
exposure to high concentrations of BPA (10−5 M) in drinking water
resulted in a modest (−19%) reduction in germ cells/mm2, indicating
that a sustained increase in apoptosis of germ cells could reduce their
number. Analysis of the individual germ cell populations demon-
strated that there was a significant reduction in the proportion of
germ cells expressing the gonocyte marker (AP2γ) with a reciprocal
increase in pre-spermatogonial (MAGEA4) population. These findings
are consistent with a reduction in gonocytes or alternatively an accel-
eration in the normal germ cell differentiation from gonocyte to pre-
spermatogonium following BPA exposure (Eladak et al., 2018).
Summary—bisphenols
Animal studies investigating effects of BPA exposure on fetal testis
development have reported inconsistent results for indicators of tes-
tosterone production and germ cell development. Similarly, results of
epidemiological studies investigating association between BPA and
clinical indicators of reduced fetal testosterone (cryptorchidism and
hypospadias) are inconsistent. For experimental studies involving
human testis tissue, whilst the results of in-vitro experiments indicate
the potential for BPA to reduce testosterone production from the
fetal testis, this has been under basal conditions and xenograft studies
have failed to demonstrate similar effects in either first or second tri-
mester human fetal testis under gonadotrophin stimulation, as occurs
in normal pregnancy. Furthermore, typical human exposure is likely
to be well below the concentrations used for experimental studies
involving animal(s) or human tissues based on meta-analysis and latest
data on human BPA exposure using LC/MS/MS (Teeguarden et al.,
2016). Whilst germ cell effects have been described in one small
study involving human fetal testis xenografts and relatively high BPA
exposure (Eladak et al., 2018), future studies should focus on expo-
sures within the human-relevant range and on potential effects during
different periods of gestation in order to determine the potential for
effects on germ cells and future fertility in humans.
Pesticides and fungicides
Pesticides and fungicides represent a heterogeneous group of chemicals
widely used in agriculture. Many of these agents (e.g. Vinclozolin,
Procymidone and prochloraz) are known to have anti-androgenic proper-
ties (Albert and Jegou, 2014). Whilst reproductive effects of many of these
agents have been investigated in animal models (Taxvig et al., 2013) and
epidemiological studies (Bonde et al., 2016), relatively few have been stud-
ied in experimental models involving the use of human tissues.
Animal studies
Several pesticides and fungicides have been proposed to be anti-
androgenic with potential to impact testicular development and
function in animal studies (Taxvig et al., 2013). This includes in-vivo
studies demonstrating effects of in-utero exposure to the fungicides
Procymidone (Ostby et al., 1999) or Prochloraz (Vinggaard et al.,
2005) on fetal testosterone production in experimental animals.
Given that these agents are known to act as anti-androgens via inter-
fering directly with the androgen receptor (Robitaille et al., 2015), it
can be hypothesized that effects occurring in rodent models might be
more likely to be translated into human effects, as opposed to other
agents (e.g. phthalates) in which the mechanism of action is less clear.
Epidemiology
Whilst a number of epidemiological studies have reported associa-
tions between in-utero exposure to selected pesticides and the devel-
opment of male reproductive disorders (Bonde et al., 2016), the
majority of these studies involve different pesticides or exposure peri-
ods (e.g. outside the fetal period) to those investigated in experimen-
tal studies using human tissues. For studies in which human
experimental data is available, epidemiological data exists only for
Dieldrin (Damgaard et al., 2006; Shen et al., 2008). Higher concentra-
tions of Dieldrin have been reported in the placentae of Danish com-
pared to Finnish women. This correlates at the population level with
the higher prevalence of cryptorchidism in Denmark than in Finland
(Shen et al., 2008); however, a study of Danish subjects from the
same cohort did not identify a significant association between
Dieldrin in breast milk and the development of cryptorchidism, when
compared to controls (Damgaard et al., 2006).
Experimental evidence from human studies
Experimental studies investigating the effects of exposure to pesti-
cides on human fetal testicular development and function are limited.
To date, only two studies have reported the effects of pesticide
exposure on human fetal testis tissue/cells (Table IV). This includes a
study investigating the effects of Dieldrin, an insecticide, on second
trimester (14–16 GW) human fetal testis in an in-vitro system.
Hormones. Exposure to concentrations of Dieldrin relevant to envir-
onmental and maternal serum levels in pregnancy (10−12 M to
10−9 M) did not affect testosterone production under basal condi-
tions; however, testosterone (−30%) and gene expression of the
steroidogenic enzyme ‘steroidogenic acute regulatory protein’ (StAR)
were significantly reduced under LH-induced conditions (Fowler
et al., 2007). No effect of Dieldrin exposure was found on AMH pro-
duction from Sertoli cells. A more recent study investigated the effect
of a wide variety of chemicals, including pesticides, on testosterone
production in human fetal testis using an in-vitro culture system
(Gaudriault et al., 2017). This study identified dose-dependent reduc-
tions in testosterone as a result of exposure to a range of pesticides
including imazalil, propiconazole, bitertanol, prochloraz, chlordecone,
and for the majority of these chemicals, exposure to ~10−5 M
resulted in a 50% reduction in testosterone production compared to
basal. For glyphosate and atrazine, there was no clear reduction in
testosterone across the entire dose range and for ortho-
phenylphenol, a reduction in testosterone was only demonstrated at
the highest concentration (10−4 M).
Germ cells. Potential effects of exposure to pesticides and antifungals
on germ cell development in the human fetal testis have been
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Table IV Summary of experimental studies investigating effects of pesticide exposure in human fetal testis tissue.
Model and regimen Results
Exposure Model Fetal age (weeks) Dose Route Regimen Supplemented Testosterone AMH INSL3 Germ cells Study Comments
4-Octylphenol In-vitro 6–12 10−5 M Media 3 weeks Nil ↓ Bendsen et al. (2001)
Atrazine In-vitro 10–12 10−9 to 10−5 M Media 72 h hCG ↔ Gaudriault et al. (2017)
Bitertanol In-vitro 10–12 10−7 M Media 72 h hCG ↔ Gaudriault et al. (2017)
In-vitro 10–12 10−6 to 10−5 M Media 72 h hCG ↓ (50-75%) Gaudriault et al. (2017)
Chlordecone In-vitro 10–12 10−7 to 10−6 M Media 72 h hCG ↔ Gaudriault et al. (2017)
In-vitro 10–12 10−5 to 10−4 M Media 72 h hCG ↓ (50–90%) Gaudriault et al. (2017)
Dieldrin In-vitro 14–16 10−12 to 10−9 M Media 24 h Nil ↔ ↔ Fowler et al. (2009)
In-vitro 14–16 10−12 to 10−9 M Media 24 h LH ↓ (30%) ↔ Fowler et al. (2009)
Glyphosate In-vitro 10–12 10−8 to 10−4 M Media 72 h hCG ↔ Gaudriault et al. (2017)
Imazalil In-vitro 10–12 10−6 M Media 72 h hCG ↔ Gaudriault et al. (2017)
In-vitro 10–12 10−5 to 10−4 M Media 72 h hCG ↓ (50–100%) Gaudriault et al. (2017)
Ortho-PhenylPhenol In-vitro 10–12 10−7 to 10−5 M Media 72 h hCG ↔ Gaudriault et al. (2017)
In-vitro 10–12 10−4 M Media 72 h hCG ↓ (40%) Gaudriault et al. (2017)
Prochloraz In-vitro 10–12 10−8 M Media 72 h hCG ↔ Gaudriault et al. (2017)
In-vitro 10–12 10−7 to 10−6 M Media 72 h hCG ↓ (20–75%) Gaudriault et al. (2017)
Propiconazole In-vitro 10–12 10−7 M Media 72 h hCG ↔ Gaudriault et al. (2017)
In-vitro 10–12 10−6 to 10−5 M Media 72 h hCG ↓ (40–75%) Gaudriault et al. (2017)
Significant effects associated with adverse outcomes are highlighted in red, no change or significant effects not expected to result in adverse outcomes are highlighted in green.
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investigated in one study (Bendsen et al., 2001). The effects of 4-
octylphenol, a surfactant used as a component of several pesticides,
were investigated in prolonged (3 weeks) culture of first trimester
(6–12 GW) human fetal testis tissue. Exposure resulted in a significant
decrease in the mitotic index and in the number of spermatogonia
per unit area compared to vehicle-exposed controls (Bendsen et al.,
2001).
Summary—pesticides and fungicides
Evidence for effects of several pesticides have been described in a
limited number of experimental studies using human fetal testis tis-
sues. The majority of the agents investigated thus far have demon-
strated a reduction in testosterone production following short term
in-vitro culture. However, the relationship between the concentra-
tions used for each individual agent and measures of human exposure
remain to be elucidated. Furthermore, the possibility of correlating the
results of epidemiological and experimental studies is hindered by the
variation in agents investigated by each approach.
Pharmaceuticals
Over recent years, there has been increasing interest in the potential
effects of pharmaceutical exposure during pregnancy on reproductive
development and subsequent reproductive function in the offspring.
The use of pharmaceuticals during pregnancy results in direct expos-
ure to mother and the developing fetus. Therefore exposure to rela-
tively high concentrations of the circulating drug may result, which
contrasts with the very low level exposure to environmental chemicals
such as those described above. In addition, for some pharmaceuticals
(e.g. analgesics) the frequency of use during pregnancy may be high
resulting in sustained exposures.
Analgesics
Analgesics are the most commonly used medications worldwide.
Several of these are available without prescription and it has been
reported in many countries that 50–90% of women will use an anal-
gesic at some stage during pregnancy (Kristensen et al., 2016).
Paracetamol (acetaminophen) is the most commonly used analgesic,
whilst non-steroidal anti-inflammatory drugs (NSAIDs) including ibu-
profen are also used by up to 15% of pregnant women (Kristensen
et al., 2016).
Animal studies
Paracetamol exposure reduced fetal androgen production in rodents
in studies using both in-vivo and in-vitro approaches (Kristensen et al.,
2011, 2012; Axelstad et al., 2014; Holm et al., 2015; van den Driesche
et al., 2015a), similar to findings for aspirin exposure following in-vivo
(20% reduction in AGD) (Gupta and Goldman, 1986) or in-vitro (70%
reduction in testosterone) (Kristensen et al., 2012) exposure. For
indomethacin exposure in mice, results are conflicting in terms of fetal
testosterone production, with one in-vivo study describing a 20%
reduction in AGD (Gupta and Goldman, 1986), whilst rat studies
described either no effect in vivo (Dean, Mungall et al., 2013), or a
30% reduction in fetal testosterone production in vitro (Kristensen
et al., 2012).
Epidemiology
The majority of studies that investigated associations between mater-
nal analgesic exposure and cryptorchidism in male offspring have
reported a significant positive association (Berkowitz and Lapinski,
1996; Jensen et al., 2010; Kristensen et al., 2011; Snijder et al., 2012),
although this is not a consistent finding (Philippat et al., 2011). The
timing of maternal exposure may be a key factor as most associations
are reported to occur following prolonged exposure (>4 weeks)
(Jensen et al., 2010) or during the second trimester (Hurtado-
Gonzalez and Mitchell, 2017), which would coincide with at least part
of the postulated critical human MPW period (8–14 GW) (Welsh
et al., 2008). A reduction in fetal testosterone production, as demon-
strated in experimental studies described above, could provide a
mechanistic explanation for paracetamol-induced cryptorchidism in
male offspring, although proving this in humans is challenging.
However, measurement of the AGD in offspring can provide an indir-
ect read-out of fetal androgen production, linking the reported asso-
ciation with the proposed mechanism (Dean and Sharpe, 2013). A
recent study has shown an association between paracetamol expos-
ure (inclusive of the MPW) and reduced AGD in boys up to 24
months, independent of body size (Fisher et al., 2016). Nevertheless,
for these epidemiological studies, extrapolation of results to direct
clinical effects should be considered with caution, primarily due to
the lack of direct analgesic measurements and the reliance on retro-
spective questionnaires for exposure classification which may involve
a degree of recall bias.
Experimental evidence from human studies
Several recent studies have investigated the effect of analgesics on
human fetal testis using experimental models (Table V).
Paracetamol - Hormones. In-vitro studies using first trimester testis
(8–12 GW) exposed to paracetamol (10−5 M) for 1–3 days did not
alter testosterone production, compared with vehicle controls
(Mazaud-Guittot et al., 2013). This was also the case for the para-
cetamol metabolite AM404 (10−5 M) (Mazaud-Guittot et al., 2013).
A recent study using an organotypic in-vitro culture system of first tri-
mester human fetal testes explants showed that exposure to para-
cetamol in a dose range of 10−8 to 10−6 M increased testosterone by
25%; however, higher doses of 10−5 M and 10−4 M did not have any
effect on testosterone production (Gaudriault et al., 2017).
The conflicting results between rodent and human in-vitro studies
may relate to the stage of testis development (i.e. timing within the
MPW) or differences in the experimental system (Mazaud-Guittot
et al., 2013). Caution should be exercised when relating effects using
in-vitro models to the in-vivo situation in humans, as the former cannot
directly recapitulate normal pharmacokinetics, including in-vivo peak
and trough concentrations. To circumvent some of the potential lim-
itations of the in-vitro approaches for the human fetal testis, subse-
quent studies have utilized an ex-vivo approach involving subcutaneous
xenografting of human fetal testis tissues (n = 5; 14–20 GW) into host
castrate nude mice. Oral exposure of these mice to a human-relevant
regimen of paracetamol (20 mg/kg; three times daily) for 1 week sig-
nificantly reduced (−45%) host serum testosterone and seminal ves-
icle (androgen dependent organ) weight (−18%), unlike a single daily
exposure which had no effect on either parameter (van den Driesche
et al., 2015a). Further confirmation of the human relevance of
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Table V Summary of experimental studies investigating effects of analgesic exposure in human fetal testis tissue.
Model and regimen Results
Exposure Model Fetal age
(weeks)
Dose Route Regimen Supplemented Testosterone AMH INSL3 Germ Cells Study Comments
Paracetamol In-vitro 8–11 10−5 M Media 7d Nil ↓ Hurtado-Gonzalez et al. (2018)
In-vitro 8–12 10−5 M Media 24–72 h hCG ↔ ↓* ↔ Mazaud-Guittot et al. (2013) *Dose response ↓
In-vitro 10–12 10−5 to 10−4 M Media 72 h hCG ↔ Gaudriault et al. (2017)
In-vitro 10–12 10−8 to 10−6 M Media 72 h hCG ↑ (25%) Gaudriault et al. (2017)
Xenograft 14–20 60 mg/kg/d Oral Gavage 7d hCG ↓ van den Driesche et al. (2015a)
Xenograft 14–20 60 mg/kg/d Oral Gavage 7d hCG ↓ Hurtado-Gonzalez et al. (2018)
Xenograft 14–20 60 mg/kg/d Oral Gavage 1d hCG ↔ van den Driesche et al. (2015a)
Xenograft 14–20 60 mg/kg/d Oral Gavage 1d hCG ↓ Hurtado-Gonzalez et al. (2018)
Ibuprofen Xenograft 14–17 60 mg/kg/d Oral Gavage 7d hCG ↔ ↔ Ben Mamaar (2017)
Xenograft 14–20 60 mg/kg/d Oral Gavage 1d hCG ↓ Hurtado-Gonzalez et al. (2018)
Xenograft 14–20 60 mg/kg/d Oral Gavage 7d hCG ↓ Hurtado-Gonzalez et al. (2018)
In-vitro 7–8 10−5 M Media 72 h hCG ↔ ↓ Ben Mamaar (2017)
In-vitro 8–10 10−5 to 10−4 M Media 72 h hCG ↓ ↓ ↔ ↔ Ben Mamaar (2017)
In-vitro 8–10 10−7 to 10−6 M Media 72 h hCG ↔ ↓** ↔ Ben Mamaar (2017) **10−7 only
In-vitro 8–11 10−5 M Media 7d Nil ↓*** Hurtado-Gonzalez et al. (2018) ***Gonocytes only
In-vitro 10–12 10−7 to 10−4 M Media 24–72 h hCG ↔ ↔* ↔* Ben Mamaar (2017) *Dose response ↓
In-vitro 10–12 10−8 to 10−5 M Media 72 h hCG ↔ Gaudriault et al. (2017)
In-vitro 10–12 10−4 M Media 72 h hCG ↑ Gaudriault et al. (2017)
Aspirin In-vitro 8–10 10−7 M Media 72 h hCG ↔ Mazaud-Guittot et al. (2013)
In-vitro 8–10 10−6 to 10−4 M Media 72 h hCG ↑ ↑# ↔ Mazaud-Guittot et al. (2013) #Only tested at
10−5 (8–12 GW)
In-vitro 10–12 10−7 to 10−4 M Media 72 h hCG ↔ ↔## Mazaud-Guittot et al. (2013) ##Only tested at
10−5
In-vitro 10–12 10−8 to 10−4 M Media 72 h hCG ↔ Gaudriault et al. (2017)
Indomethacin In-vitro 8–12 10−5 M Media 72 h hCG ↑ (20%) ↔### ↔ Mazaud-Guittot et al. (2013) ###(10–12 GW)
In-vitro 10–12 10−8 to 10−5 M Media 72 h hCG ↔ Gaudriault et al. (2017)
In-vitro 10–12 10−4 M Media 72 h hCG ↑ (20%) Gaudriault et al. (2017)
Aniline In-vitro 10–12 10−8 to 10−5 M Media 96 h hCG ↔#### Gaudriault et al. (2017) ####↓ 20% (10−7)
Significant effects associated with adverse outcomes are highlighted in red, no change or significant effects not expected to result in adverse outcomes are highlighted in green.
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paracetamol exposure is evident from the finding that 1 h after the
final dose in host mice, plasma paracetamol concentrations were sig-
nificantly lower than post-therapeutic levels reported in pregnant
women (Rayburn et al., 1986). However, it must be considered that
circulating paracetamol levels in pregnant women may not be a direct
indicator of intra-testicular levels in the developing fetus.
Insl3 hormone production was significantly reduced in first trimes-
ter human fetal testis cultures exposed to paracetamol, in which a
clear dose–response relationship with increasing paracetamol expos-
ure (at 10−7 M to 10−4 M) was demonstrated (Mazaud-Guittot et al.,
2013).
Paracetamol - Germ cells. An in-vitro study using first trimester human
fetal testis (8–12 GW) exposed to paracetamol (10−5 M) for 1–3
days found no alteration in germ cell number (Mazaud-Guittot et al.,
2013). However, a more recent in vitro study with a longer period (7
days) of exposure showed that similar paracetamol concentration
(10−5 M) significantly reduced (−28%) gonocyte number (Hurtado-
Gonzalez et al., 2018). The differing findings in these studies may
reflect the longer period of exposure in the latter study or may be
the result of differences in the culture systems. To further investigate
the potential effect of paracetamol exposure on the human fetal tes-
tis, a xenograft approach was also used alongside the in-vitro model
(Hurtado-Gonzalez et al., 2018). Xenografted second trimester tissue
(14–20 GW) exposed to paracetamol using a human-relevant expos-
ure regimen (20 mg/kg, three times daily) resulted in a reduction in
gonocyte number after 7 days exposure (−32%). Interestingly, a
reduction in gonocyte number (−17%) was also demonstrated after
just 1 day of exposure to paracetamol (Hurtado-Gonzalez et al.,
2018).
Whilst most of circulating paracetamol in humans comes from use
of paracetamol-containing medications, an alternative source has also
been described. The industrial chemical aniline, which is found in a
wide variety of manufactured products, such as rubber, pharmaceuti-
cals, cosmetics and cigarette smoke, is rapidly metabolized to paraceta-
mol inside the body (Modick et al., 2014, 2016). Furthermore, in-vivo
studies in which male mice exposed in utero to aniline have shown simi-
lar fetal anti-androgenic effects to those described for exposure to
paracetamol (Holm et al., 2015). Only one study has investigated the
effect of aniline on the human fetal testis (Gaudriault et al., 2017). In-
vitro exposure of first trimester (10–12GW) human fetal testis to anil-
ine for 96 h had no effect on testosterone production across a range of
doses (10−8 M to 10−5 M) apart from a small reduction (−20%) for an
intermediate concentration (10−7 M) (Gaudriault et al., 2017).
Ibuprofen - Hormones. Exposure of first trimester human fetal testis
explants to ibuprofen using an organotypic culture system did not
affect testosterone production (Gaudriault et al., 2017). However,
another in-vitro study reported a reduction in steroidogenic enzyme
expression across a similar range of concentrations (10−4 M, 10−5 M).
This effect was only evident for early first trimester testes (8–9 GW),
as there was no effect at any other gestational time-point examined
(<8 GW or >10 GW) (Ben Maamar et al., 2017). Similarly, there was
no effect of exposure to ibuprofen on testosterone production in
host mice carrying xenografts of second trimester human fetal testis
tissue (Ben Maamar et al., 2017).
Ibuprofen exposure for 3 days in an in-vitro model reduced AMH in
first trimester human fetal testes at 7–8 GW (10−5 M), and at
8–10 GW (10−4 M to 10−5 M); however, no significant difference in
AMH was found after 7 days of exposure of host mice carrying
second trimester human fetal testis xenografts (Ben Maamar et al.,
2017).
Insl3 production was not affected in early first trimester
(8–10 GW) human fetal testis following in-vitro culture with ibuprofen,
whilst for late first trimester (10–12 GW) testis, an overall dose
response reduction was demonstrated (Ben Maamar et al., 2017).
The fact that ibuprofen exposure affects testosterone and Insl3 pro-
duction only during specific periods of human fetal testis develop-
ment, has implications for the potential of this analgesic to impact
testis descent, i.e. cryptorchidism (which is under the control of these
two hormones).
Ibuprofen - Germ cells. In-vitro culture and exposure of first trimester
human fetal testis to ibuprofen for 7 days resulted in a reduction in
gonocyte number (−22%). However, there were no significant
changes to germ cell number following exposure of second trimester
xenografted testis tissue (Hurtado-Gonzalez et al., 2018).
Aspirin - Hormones. Aspirin exposure of first trimester testis explants
in an organotypic culture system, did not alter testosterone produc-
tion across a range of concentrations (10−4 to 10−8 M) (Gaudriault
et al., 2017). However, in a separate in-vitro culture study, a significant
dose–response relationship was reported whereby aspirin exposure
for 3 days significantly increased the production of testosterone by
early first trimester (8–9 GW), but not in late first trimester
(10–12 GW) testes (Mazaud-Guittot et al., 2013). In-vitro exposure of
human fetal testis (10–12 GW) to aspirin for 3 days did not affect
Insl3 production (Mazaud-Guittot et al., 2013), whereas AMH pro-
duction was significantly increased.
Aspirin - Germ cells. In-vitro exposure to aspirin did not affect germ
cell number in first trimester (8–10 GW) human fetal testis tissue
(Mazaud-Guittot et al., 2013).
Indomethacin - Hormones. Similar to rodent studies, there are conflict-
ing results of experimental studies using in-vitro culture of human fetal
testis. Exposure of first trimester human fetal testis explants
(10–12 GW) to indomethacin (10−4 M) for 72 h, reduced testoster-
one (−20%), whereas exposure at lower concentrations (10−5 M to
10−8 M) had no effect (Gaudriault et al., 2017). In contrast, a previous
study found that indomethacin exposure (10−5 M) increased testos-
terone production (+20%), when first trimester (8–12 GW) testes
were exposed in-vitro for a similar duration (Mazaud-Guittot et al.,
2013). In-vitro exposure of human fetal testis (10–12 GW) to indo-
methacin (10−5 M) for 2 days did not affect Insl3 production
(Mazaud-Guittot et al., 2013).
Indomethacin - Germ cells. In-vitro exposure to indomethacin (10−5 M)
for 2 days did not affect germ cell number in first trimester
(8–12 GW) human fetal testis cultures (Mazaud-Guittot et al., 2013).
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Summary—analgesics
Exposure to analgesics has been linked to abnormalities in testicular
function and development of male reproductive disorders across a
range of studies. This includes epidemiological and experimental stud-
ies using animal and human tissues. Results regarding testosterone
production are not consistent and this may reflect differences
between species, model systems or dose, timing and duration of
exposure (Table I and Fig. 2). However, there is increasing evidence
from human studies that paracetamol and ibuprofen can affect germ
cell number in the fetal testis and evidence exists for similar effects
on germ cells in the fetal ovary (Hurtado-Gonzalez et al., 2018).
These studies involve exposure to human-relevant concentrations of
these drugs and for xenograft studies they include comparable dosing
regimens to those used therapeutically in humans. Whilst the evi-
dence for effects of paracetamol and ibuprofen on germ cells appears
robust, the potential for such exposures to impact subsequent male
reproductive function and fertility are unexplored. Indeed, it is pos-
sible that there may be compensation later in gestation or during
childhood that would rescue the effects of any fetal germ cell loss.
Large-scale prospective epidemiological studies and longer-term
experimental (e.g. xenograft) studies can help to address this particu-
lar question.
Diethylstilboestrol
Diethylstilboestrol (DES) is a synthetic estrogen that was used clinic-
ally to prevent spontaneous miscarriage and pre-term labor from the
1940 s until the early 1970 s (Marselos and Tomatis, 1992). DES was
withdrawn from clinical use after the demonstration of a causal role
in the development of vaginal carcinoma in girls born to exposed
mothers (Herbst et al., 1971). In addition to the effects on female off-
spring, an association with structural abnormalities of the male repro-
ductive tract was also described including epididymal cysts,
microphallus and testicular hypoplasia (Toppari et al., 1996).
Animal studies
Animal studies involving in-vitro culture of rat and mouse fetal testis,
have reported a reduction in testosterone production following
exposure to DES (N’Tumba-Byn et al., 2012), similar to the results of
previous in-vitro studies involving fetal mice (Delbes et al., 2005) and
in-vivo studies in rats (Haavisto et al., 2001).
Epidemiology
For TDS disorders, which are linked to a reduction in androgen
action during fetal life, there is conflicting evidence regarding their
association with maternal DES exposure. Three studies have
reviewed the literature relating to exogenous estrogen exposure and
male reproductive disorders (Toppari et al., 1996; Storgaard et al.,
2006; Martin et al., 2008). Whilst early studies reported that hypo-
spadias was significantly associated with DES exposure (Henderson
et al., 1976), it has subsequently been pointed out that this related to
urethral abnormalities resulting from exposure to exogenous estro-
gens (including DES), which may have resulted from abnormalities in
penile development rather than an effect on urethral formation as a
result of reduced androgen exposure (Joffe, 2002). The meta-analysis
of all available evidence revealed a significant association between
DES exposure and hypospadias; however, it was concluded that any
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effect of DES on hypospadias is likely to be small (Martin et al.,
2008). For cryptorchidism, an increased risk in association with DES
exposure is reported; however, this was dependent on the statistical
model used and was indicative of heterogeneity (Martin et al., 2008).
A subsequent cohort study has reported an association between in-
utero exposure to DES and an increased risk of cryptorchidism, how-
ever, only for those in whom the initial exposure occurred prior to
the 11th week of gestation with no significant association following
exposure after 11 GWs (Palmer et al., 2009). Studies have demon-
strated no effect of prenatal DES exposure on sperm counts (Leary
et al., 1984) or fertility (Wilcox et al., 1995); however, this is in con-
trast to a previous study demonstrating an association between pre-
natal exposure to DES and semen parameters in adult men (Gill
et al., 1979). Importantly, this study included analysis of men born to
a large cohort of mothers who participated in an RCT involving DES
exposure during pregnancy.
Experimental evidence from human studies
To date, only two studies have investigated the effect of DES expos-
ure on the human fetal testis (Table VI). In-vitro organ culture of first
trimester human fetal testis exposed to DES (10−5 to 10−6 M) for 3
days did not alter testosterone production (N’Tumba-Byn et al.,
2012). Interestingly, this study compared effects of DES exposure in
rodent and human fetal testis demonstrating contrasting results
between species using an identical experimental system (N’Tumba-
Byn et al., 2012).
In a separate study using the xenograft model, exposure to DES
(100μg/kg, three times weekly) for 35 days resulted in no significant dif-
ference in testosterone production by second trimester (15–19GW)
testis tissue. Interestingly, host mouse seminal vesicles were significantly
increased in weight, which was indicative of increased testosterone pro-
duction from the xenografted tissue over the entire grafting period
(Mitchell et al., 2013). The reason for this unexpected increase in tes-
tosterone is unclear.
Summary—diethylstilboestrol
Whilst rodent studies have indicated a profoundly negative effect of
DES exposure on testosterone production by the fetal testis
(Haavisto et al., 2001; Delbes et al., 2005; N’Tumba-Byn et al.,
2012), experimental studies utilizing human fetal testis tissues have
failed to identify similar effects (N’Tumba-Byn et al., 2012; Mitchell
et al., 2013), which may relate to the presence of ESR1 in rodent
Leydig cells, and the absence of this estrogen receptor in human fetal
testis (Mitchell et al., 2013). Epidemiological data suggests that any
potential effect of DES exposure on male reproductive development
is likely to be of small magnitude. Taken together the results suggest
an important species difference in terms of DES effects on fetal tes-
tosterone production which may explain why this frequently results
in the development of male reproductive disorders in rodents, whilst
associations between DES and subsequent male reproductive disor-
ders in humans are rather modest. Whilst DES is unlikely to be used
in pregnant women in the future, the findings of this study offer some
reassurance regarding the potential of low-level exposure to environ-
mental estrogens to affect human male reproductive development,
given their extremely low potency compared with DES and the high
exposures that resulted from therapeutic use of DES.
Metformin
Metformin is a biguanide used as an insulin sensitizer in the treatment
of Type 2 Diabetes and obesity. Metformin may also be prescribed
during pregnancy in individuals with pre-existing diabetes or those that
have developed gestational diabetes during their pregnancy (https://
bnf.nice.org.uk/drug/metformin-hydrochloride.html#pregnancy).
Animal studies
Exposure to metformin has been shown to reduce testosterone pro-
duction in mouse fetal testis following in-vitro or in-vivo exposure.
Exposure of pregnant mice to metformin (300 mg/gk/d) from
embryonic day (e) 0.5 resulted in a significant reduction in testoster-
one at e16.5 (Tartarin et al., 2012).
Epidemiology
To date, there has been no epidemiological data relating in-utero
exposure to metformin to TDS disorders at birth, although one study
found no association between prepubertal testicular volumes in off-
spring born to mothers who had received metformin, compared with
insulin, for gestational diabetes (Tertti et al., 2016).
Experimental evidence from human studies
A recent study has investigated the effect of metformin exposure on
the human fetal testis using an in-vitro culture system (Tartarin et al.,
2012) (Table VI). Exposure to a range of metformin concentrations
(5×10−5M to 5×10−3M) resulted in a significant decrease in testos-
terone production from the testis. Importantly, the lowest concentra-
tion (5×10−5M) reflects the serum levels measured in humans
following a therapeutic dose of metformin (Robert et al., 2003).
Azole antifungals and abiraterone
Azole antifungals (e.g. ketoconazole, fluconazole) and abiraterone are
drugs known to inhibit key enzymes of the steroidogenic pathway
including P450scc (CYP17A1; ketoconazole) and CYP17A1 & 3βHSD
(abiraterone). As a result, exposure of the fetal testis to these agents
could be predicted to affect testosterone production and potentially
to result in the development of male reproductive disorders.
Epidemiology
Exposure to ‘azole’ antifungals that interfere with steroidogenesis
may be relevant to pregnancy, given that they are frequently pre-
scribed for the treatment of vaginal candidiasis. No association
between maternal use of antifungals and hypospadias has been
reported in two studies (Carter et al., 2008) (Norgaard et al., 2008),
or for AGD after exposure to antifungals administered as vaginal
tablets or as topical cream (Mogensen et al., 2017). However, the lat-
ter study demonstrated a significant association between oral flucon-
azole and reduced AGD in the male offspring (Mogensen et al.,
2017). Importantly, for each of these three studies, the numbers of
cases was small and larger prospective studies would be required to
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provide definitive evidence of associations between antifungals and
indicators of fetal testosterone production.
Experimental evidence from human studies
Exposure to ketoconazole results in a significant reduction (50–90%)
in testosterone following in-vitro exposure of first trimester human
fetal testis for 96 h (Gaudriault et al., 2017) (Table VI). Similar results
have been described for ketoconazole with a progressive reduction
in testosterone production after 24 h (−20%), 48 h (−90%) and 72 h
(−95%), compared to vehicle-exposed tissue (Mazaud-Guittot et al.,
2013). This study also reported a ketoconazole-induced reduction in
INSL3 (−100%) and AMH (−50%) after 72 h of culture.
Abiraterone (an anti-androgen used in prostate cancer) has also
been shown to result in a reduction in testosterone production
(−80%) in second trimester human fetal testis xenografts (grafted for
14 days), whilst no effect on germ cell number was demonstrated
(Spade et al., 2014) (Table VI). Indeed, these agents may be con-
sidered as positive controls for studies investigating the effects of
exposures on testosterone production in human fetal testes
(Mazaud-Guittot et al., 2013; Spade et al., 2014).
Other pharmaceuticals
A recent study has described the effect of exposure to 27 different
chemicals, including several additional pharmaceuticals, on the human
fetal testis using an in-vitro system (Gaudriault et al., 2017) (Table VI).
A dose dependent reduction in testosterone production was deter-
mined for clomiphene (an anti-estrogenic substance used to stimulate
ovulation), theophylline (a methylxanthine drug which acts as a non-
selective phosphodiesterase inhibitor used in asthma) and valproate
(an anti-epileptic) following in-vitro culture of human fetal testis tissue
for 96 h (Gaudriault et al., 2017). Interestingly, valproate has been
associated with hypospadias in male offspring of exposed mothers
(Veroniki et al., 2017).
Lifestyle
Exposures that relate to lifestyle may also impact on the development
of male reproductive disorders. However, to date only a limited
number of studies using human fetal tissues have been conducted in
this area (Table VII).
Xanthines
Xanthines are a class of compounds that share a common structure
and have stimulant properties, including caffeine, one of the most
commonly used recreational drugs worldwide. Effects of several of
these compounds have been investigated in vitro (Gaudriault et al.,
2017).
Experimental evidence from human studies
No negative effects on testosterone production from cultured human
fetal testis tissue were demonstrated following exposure to caffeine,
paraxanthine, theobromine or 1,3,7 trimethyluric acid (TMUA), albeit
there appeared to be a modest decrease in testosterone production
for caffeine only at the lowest concentration (Table VII).
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Alcohol
Alcohol exposure during pregnancy is known to impact on fetal
development, and its mechanism of action could occur centrally or in
the placenta. Fetal alcohol syndrome is well described and can
include neurodevelopmental disorders, facial dysmorphism and
growth abnormality (Nash and Davies, 2017).
Epidemiology
An epidemiological study involving a Danish–Finnish cohort (~2500
boys), demonstrated an association between maternal alcohol consump-
tion and increased risk of cryptorchidism in sons (Damgaard et al., 2007).
Experimental evidence from human studies
The effect of exposure to alcohol on human fetal testis has only been
investigated in one study (Table VII). Interestingly, exposure of first
trimester human fetal testis to ethanol (10−8 M to 10−5 M for 72 h)
using in-vitro culture resulted in a significant increase in testosterone
production across a wide dose range (Gaudriault et al., 2017).
Smoking
Maternal smoking is known to have many potentially harmful effects
on the developing fetus including intra-uterine growth retardation and
low birth weight (Abraham et al., 2017).
Epidemiology
Epidemiological studies have measured sperm counts in men exposed in-
utero to maternal cigarette smoke, which demonstrated a reduction in
sperm concentration (38–48%) in exposed- compared to unexposed-
men (Storgaard et al., 2003; Ramlau-Hansen et al., 2007). Use of nico-
tine substitutes during pregnancy significantly increased the risk of crypt-
orchidism in male offspring (Damgaard et al., 2008) and an association
between maternal smoking during pregnancy and cryptorchidism in male
offspring has also been demonstrated (Jensen et al., 2007).
Experimental evidence from human studies
Hormones. One study compared testosterone levels in plasma of
human fetuses exposed to maternal cigarette smoke with those of
non-smoking mothers and found no difference in testosterone
between the groups despite a significant reduction in hCG (Fowler
et al., 2009).
Germ cells. The effects of maternal smoking on human fetal testis has
been investigated in two experimental studies, both of which used
exposure to components of cigarette smoke (Coutts et al., 2007;
Angenard et al., 2010). In-vitro exposure of human fetal testis to
DMBA-DHD, the active metabolite of polyaromatic hydrocarbons
found in cigarette smoke, resulted in a significant increase in apop-
tosis in germ cells, which could be rescued by antagonism of the aryl
hydrocarbon receptor (AHR), indicating that activation of the AHR is
the likely mechanism for the effects of DMBA-DHD on germ cells
(Coutts et al., 2007). Cadmium (another component of cigarette
smoke)-exposure of first trimester human fetal testis resulted in
increased apoptosis in germ cells, without any effect on testosterone
production (Angenard et al., 2010).
Mixtures
Over recent years, it has been increasingly recognized that the impact
of environmental exposures depends not only on the individual
agents, but also on the combination of agents. A number of animal
studies have investigated the effects of ‘mixtures’; however, to date
such approaches using human fetal testis tissues is limited. A key
aspect of this is whether the effects can be considered as additive or
synergistic. The effect of four separate mixtures (all including BPA)
has been investigated in a recent study involving in-vitro exposure of
first trimester human fetal testis for 96 h (Gaudriault et al., 2017).
This included two mixtures (four agents each) of BPA + pharmaceuti-
cals and two mixtures (eight agents each) which included additional
environmental (pesticides and bisphenols) chemicals.
As expected, each mixture resulted in a reduction in testosterone
production. Importantly, the authors compared the individual dose–
response results to those predicted by the additive effect of the indi-
vidual agents. There was a high correlation between predicted and
actual response for each of the four mixtures indicating that these
agents acted in an additive manner (Gaudriault et al., 2017). This
allows such experimental systems to use the results of exposure to
individual agents for approximation of the combined anti-androgenic
effect of multiple exposures, based on an assumption of dose-
addition. This has important implications for informing regulation of
environmental chemicals and pharmaceutical exposures.
Discussion
Whilst a relatively large body of animal data exists for determining
the impacts of in-utero exposures on fetal testicular development and
male reproductive disorders, a limited number of experimental stud-
ies involving human tissues have been conducted. Animal models
offer the potential to conduct more expansive studies involving expo-
sures across multiple developmental periods and generation of dose
response data. An additional advantage of animal studies is the possi-
bility of conducting in-vivo fetal exposure studies in animals which is
not possible for human studies which currently rely on in-vitro or ex-
vivo (xenograft) approaches. However, this review has described sev-
eral exposures for which the studies utilizing human tissues have
demonstrated important differences to those found in animals. This
may relate to differences in study design, dose administered or
exposure regimen; however, it has also been shown that many of
these differences appear to result from fundamental species differ-
ences in the effect of specific agents at human-relevant levels of
exposure. Whilst epidemiological studies can to some extent bridge
the gap between effects demonstrated in animal studies and human-
relevance, such studies cannot demonstrate direct causation or elicit
underlying mechanisms for effects; such studies are also prone to
confounding. This highlights the importance of experimental models
using human fetal tissues in determining the potential impact of in-
utero environmental and pharmaceutical exposures in humans.
Future perspectives
It is clear that understanding effects of in-utero exposures on male
reproductive development will continue to rely on interpretation of a
combination of animal studies, epidemiology and experimental studies
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utilizing human tissues. Conducting co-ordinated studies that combine
these methods represents an important approach. This may include
combining experimental studies using in-vitro and in-vivo approaches
(Kristensen et al., 2011; Hurtado-Gonzalez et al., 2018), studies com-
paring results in both rodent and human tissues (Ben Maamar et al.,
2015; Hurtado-Gonzalez et al., 2018), or combined studies of epi-
demiological and experimental evidence (Kristensen et al., 2011).
Epidemiological studies may be enhanced by developing large-scale
prospective cohort studies. This is of particular importance to ensure
that the timing of measurement of exposure coincides with the
expected mechanism of effect (e.g. in-utero exposure and cryptorchid-
ism/hypospadias identified in the neonatal period). Furthermore, for
pharmaceuticals with relatively short half-lives, which are taken inter-
mittently and do not accumulate in the body, obtaining accurate and
detailed records of exposure during pregnancy is essential. This infor-
mation is extremely difficult to obtain retrospectively and is prone to
recall bias making prospective studies crucial for such exposures.
The future for determining effects of in-utero exposure(s) on male
testicular development and reproduction is also likely to involve
refinement of existing experimental approaches. Whilst recent devel-
opment of in-vitro and xenograft approaches has allowed direct test-
ing of environmental chemicals and pharmaceuticals on the human
fetal testis, these models may be limited by tissue supply and hetero-
geneity between individuals. The recent development of organoids
for a variety of organs and tissues may prove critical for future studies
to test the effects of exposures in organoids generated from human
testicular tissues (Alves-Lopes and Stukenborg, 2017). Computational
and mathematical modeling may also be used to predict the effects of
exposure(s) in-silico (Krysiak-Baltyn et al., 2012), although this will be
dependent on the robustness of the imputation of biological data.
The scientific and public interest in the effects of chemical expo-
sures in humans is likely to continue to increase. Regulation of these
agents will increasingly rely on models that can provide direct human-
relevant data. Therefore, we propose that assessment of the experi-
mental evidence from studies using human fetal tissues should be an
integral part of informing regulatory policies in relation to the effects
of environmental and pharmaceutical exposures on male reproduct-
ive development.
Supplementary data
Supplementary data are available at Human Reproduction Update
online.
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